Monday, August 14, 2017 9:01:38 AM
: Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, “The pursuit of approval by the EMA and FDA and commercialization for entolimod as a medical radiation countermeasure remains our
top priority.”
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=12230538
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM